PPT OA Knee

77
MODALITIES OF MANAGMENT Department of Orthopedics Surgical Division MH, JRC OSTEOARTHRITIS KNEES 1

Transcript of PPT OA Knee

Page 1: PPT OA Knee

1

MODALITIES OF MANAGMENT

Department of OrthopedicsSurgical Division

MH, JRC

OSTEOARTHRITIS KNEES

Page 2: PPT OA Knee

2

MODALITIES OF MANAGMENT

By Maj S B PandeyModerator: Lt Col Ravinder Singh

OSTEOARTHRITIS KNEES

Page 3: PPT OA Knee

3

Page 4: PPT OA Knee

4

Osteoarthritis is a degenerative disorder that results from the biochemical breakdown of articular (hyaline) cartilage in the synovial joints.

However, the current concept holds that osteoarthritis involves not just the articular cartilage but the entire joint organ, including the subchondral bone and synovium.

Page 5: PPT OA Knee

5

Osteoarthritis predominantly involves the weight-bearing joints, including the knees, hips, cervical and lumbosacral spine, and feet. Other commonly affected joints include the distal interphalangeal (DIP) and proximal interphalangeal (PIP) joints of the hands.

Page 6: PPT OA Knee

6

Clinical Presentation Joint soreness after inactivity or periods of overuse

of a joint.

Stiffness after rest and disappears quickly as activity begins again.

Morning stiffness lasting no longer than 30 minutes.

Joint pain which is less in the morning and stronger at the end of the day following activity.

Muscle atrophy around joints caused by inactivity can increase pain.

Pain and stiffness can affect posture, coordination and ability to walk.

Page 7: PPT OA Knee

7

Signs of Knee Osteoarthritis may include :

pain exacerbated by moving the knee

knee locking or catching

pain when standing up from a chair

pain when going up and down stairs

weakening thigh muscles.

Page 8: PPT OA Knee

8

Radiographic appearance

Radiographic Criteria Loss of joint space

Sub-chondral sclerosis or cyst formation

Presence of new bone formation or

osteophytes

Page 9: PPT OA Knee

9

Page 10: PPT OA Knee

10

Page 11: PPT OA Knee

11

Page 12: PPT OA Knee

12

The goals of osteoarthritis treatmentPain alleviation and improvement of functional status

Non-pharmacologic interventions are the cornerstones of

osteoarthritis therapy

Patient education

Temperature modalities

Weight loss

Exercise

Physical therapy

Occupational therapy

Joint unloading in certain joints (e.g., knee, hip).

Page 13: PPT OA Knee

13

Acetaminophen has clearly been demonstrated to be effective in the treatment of pain of OA when c/w placebo for 50% pain reduction when using 1000mg.

Acetaminophen has been demonstrated to be safe up to 4 gm/day.

As OA is principally non-inflammatory NSAIDs should clearly be titrated for clinical effect.

Page 14: PPT OA Knee

14

Opioids

Tramadol is specifically identified as the initial agent of choice in patients with OA

Page 15: PPT OA Knee

15

Do Oral Medications (Acetaminophen, NSAIDs) help or hurt ?

Page 16: PPT OA Knee

16

Glucosamine Sulfate Glucosamine sulfate has measured its effectiveness on Osteoarthritis of the knee. However, there is some evidence that it might also help Osteoarthritis of the hip or spine.

In addition to relieving pain, glucosamine sulfate might also slow the breakdown of joints in people with osteoarthritis who take it long-term.

Page 17: PPT OA Knee

17

Side Effects of Glucosamine Sulfate

Glucosamine appears to be safe for most people with diabetes, but blood sugar should be monitored closely.

People with asthma should be cautious about taking products that contain glucosamine.

Page 18: PPT OA Knee

18

There is not enough reliable scientific information available to know if glucosamine sulfate is safe to take during pregnancy or while breast-feeding.

Until more is known, do not take glucosamine sulfate while pregnant or breast-feeding.

Page 19: PPT OA Knee

19

What about the role of Steroid Injections ?

Steroid injections can be used as an adjunct therapy along with systemic therapy.

This is an effective way to knock down inflammation.

Mechanism of Action

Inhibit accumulation of inflammatory cell lines

Reduction of prostaglandin synthesis Inhibit leukocyte secretion from synovial cells Decrease interleukin secretion by the

synovium Increase viscosity of synovial fluid

Page 20: PPT OA Knee

20

HYLURINIDASE

Hyalgan® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy, and to simple analgesics, e.g., acetaminophen.

Page 21: PPT OA Knee

21

Page 22: PPT OA Knee

22

NEW DRUGS

Protelosa, contain the chemical Strontium Ranelate which is thought to encourage the body to produce cartilage and is already used to treat osteoporosis.

Celecoxib : 100 to 200 mg once or twice a day.

Page 23: PPT OA Knee

23

PHYSIOTHERAPY AND

REHABILITATION

Page 24: PPT OA Knee

24

Page 25: PPT OA Knee

25

Page 26: PPT OA Knee

26

Page 27: PPT OA Knee

27

OPERATIVE PROCEDURES

Page 28: PPT OA Knee

28

HIGH TIBIAL CORRECTIVE OSTEOTOMY

Page 29: PPT OA Knee

29

Page 30: PPT OA Knee

30

Page 31: PPT OA Knee

31

Uni-Condylar/Compartmental Arthroplasty

Page 32: PPT OA Knee

32

Page 33: PPT OA Knee

33

Minimal Incision Arthroplasty

Page 34: PPT OA Knee

34

Page 35: PPT OA Knee

35

Total Knee Arthroplasty

Page 36: PPT OA Knee

36

Page 37: PPT OA Knee

37

Page 38: PPT OA Knee

38

Indications for Total Knee Joint Replacement

The main indication for Total Knee Arthroplasty is for relief of pain associated with arthritis of the knee in patients who have failed non operative treatments.

(American Academy of Orthopedics)

Page 39: PPT OA Knee

39

Page 40: PPT OA Knee

40

Page 41: PPT OA Knee

41

Page 42: PPT OA Knee

42

22 Jul 2011

(Ex- Sub) Gurmukh Singh, 65 Yrs Old case of Hypertension with Type 2 DM on medication for past 15 YrsDiagnosed with Osteoarthritis Both Knees with Varus Deformity.

Page 43: PPT OA Knee

43

Page 44: PPT OA Knee

44

Page 45: PPT OA Knee

45

Page 46: PPT OA Knee

46

Page 47: PPT OA Knee

47

133.mp4

Page 48: PPT OA Knee

48

Page 49: PPT OA Knee

49

Page 50: PPT OA Knee

50

Page 51: PPT OA Knee

51

Page 52: PPT OA Knee

52

Page 53: PPT OA Knee

53

Page 54: PPT OA Knee

54

Page 55: PPT OA Knee

55

Page 56: PPT OA Knee

56

Page 57: PPT OA Knee
Page 58: PPT OA Knee

58

Page 59: PPT OA Knee

59

Page 60: PPT OA Knee

60

Page 61: PPT OA Knee

61

Page 62: PPT OA Knee

62

Page 63: PPT OA Knee

63

Page 64: PPT OA Knee

64

Page 65: PPT OA Knee

65

Medication Strength/dose AmountFirst injection

Bupivacaine 0.5% (200-400 mg) 24 cc

Morphine sulphate 8 mg 0.8 cc

Epinephrine (1:1000) 300 μg 0.3 cc

Methylprednisolone acetate

40 mg 1 cc

Cefuroxime 750 mg 10cc (reconstituted in normal saline)

Sodium chloride 0.9% 22 cc

Second injectionBupivacaine 0.5% 20 cc

Sodium chloride 0.9% 20 cc

Ranawat Orthopedic Center (ROC) cocktail

Page 66: PPT OA Knee

66

Page 67: PPT OA Knee

67

Page 68: PPT OA Knee

68

Page 69: PPT OA Knee

69

Navigation Assisted Knee Arthroplasty

Page 70: PPT OA Knee

70

Page 71: PPT OA Knee

71

Page 72: PPT OA Knee

72

Page 73: PPT OA Knee

73

MAKOPLASTY

Navigation assisted resurfacing of joints using minimal incision

Page 74: PPT OA Knee

74

Page 75: PPT OA Knee

75

MESSAGE

Page 76: PPT OA Knee

THANKS

Page 77: PPT OA Knee

77

Question Hour